An HPLC method for the measurement of 5-fluorouracil in human plasma with a low detection limit and a high extraction yieldM A Nassim, Rakesh Goel, Farshad H. Shirazi et al.|International Journal of Molecular Medicine|2002Cited by 27
Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)–Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapiesTae‐Min Kim, Seok‐Goo Cho, Sumana Devata et al.|Blood|2025Cited by 2
SOUNDTRACK-B: A phase 2 single-arm study to evaluate the efficacy and safety of surovatamig (AZD0486) in relapsed or refractory B-cell non-Hodgkin lymphomaChan Y. Cheah, Jing‐Zhou Hou, Monique Menzies Wojtowicz et al.|Blood|2025Cited by 1